A Biotech Company 100% Focused on Pediatric Cancer Drug Development
We are not a division. We are not a side program.
Each year, 400,000 children are diagnosed with cancer—and 90,000 lose their lives. Pediatric cancers are biologically distinct from adult cancers. Yet, most children are still treated with decades-old adult drugs, causing severe long-term side effects in over 70% of survivors. For too many, especially those with some brain tumors or metastatic sarcomas, survival remains out of reach.
Different
Bridging the GAP
Despite decades of research, most promising potential cures never reach children.
Developing a new therapy requires an industry partner—but because pediatric cancer is rare, the industry looks away.
That’s why, after more than 40 years of progress in adult oncology, there are over 200 approved drugs for adults—but only seven for children.
Until now. That’s where Oncoheroes comes in.
Our Model
Focused. Collaborative. Impact-Driven
We in-license or acquire promising compounds from the industry—either discontinued or developed for other diseases but suitable for pediatric cancers—and from academic research, providing the expertise needed to bring them to patients.
Building Our Pipeline
We partner with biotech, academia, and foundations developing potential therapies for children—helping them advance treatments that align with our mission to improve pediatric cancer care.
Co-Development Partnerships
Our Name, Their Courage
We honor every child who faces cancer with unbreakable spirit.